Incidence and prognostic value of HER2-low expression metastatic breast cancer in Asian population: A 10-year retrospective study

被引：0
|
作者：
Dajsakdipon, T. [1 ]
Pipatsakulroj, W. [2 ]
Dejthevaporn, T. [3 ]
机构：
[1] Ramathibodi Hosp, Dept Med, Bangkok, Thailand
[2] Mahidol Univ, Fac Med, Ramathibodi Hosp, Dept Pathol, Bangkok, Thailand
[3] Mahidol Univ, Fac Med, Ramathibodi Hosp, Internal Med Dept, Bangkok, Thailand
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.610
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
434P
引用
收藏
页码：S364 / S364
页数：1
相关论文
共 50 条
  • [21] Landscape of HER2-low breast cancer: Insights from a six-year study on incidence and clinicopathological characteristics
    Abou Khalil, Michel
    Habibian, Lea
    Martin, Christine
    Semaan, Karl
    Khaddage, Abir
    El Kassis, Nadine
    Kesrouani, Carole
    Kourie, Hampig Raphael
    Atallah, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis
    Molinelli, C.
    Jacobs, F.
    Agostinetto, E.
    Nader-Marta, G.
    Ceppi, M.
    Bruzzone, M.
    Blondeaux, E.
    Schettini, F.
    Prat, A.
    Viale, G.
    Del Mastro, L.
    Lambertini, M.
    de Azambuja, E.
    ESMO OPEN, 2023, 8 (04)
  • [23] Prognostic value and relapse pattern of HER2-low in hormone receptor-positive breast cancer
    Wei, Tong
    Kang, Yikun
    Wang, Xue
    Yue, Jian
    Xu, Binghe
    Yuan, Peng
    THORACIC CANCER, 2024, 15 (07) : 550 - 558
  • [24] The prognostic significance of molecular subtype for male breast cancer: A 10-year retrospective study
    Yu, Xing-Fei
    Feng, Wei-Liang
    Miao, Lu-Lu
    Chen, Bo
    Yang, Hong-Jian
    BREAST, 2013, 22 (05): : 824 - 827
  • [25] The clinicopathological and prognostic significance of HER2-low breast cancer: A comparative analysis between HER2-low and HER2-zero subtypes
    Nishimura, Reiki
    Fujiki, Yoshitaka
    Taira, Tetsuhiko
    Miyaki, Toshiko
    Kanemitsu, Shuichi
    Yotsumoto, Daisuke
    Teraoka, Megumi
    Kawano, Junko
    Gondo, Naomi
    Mitsueda, Reiko
    Baba, Shinichi
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yoshiaki
    Sagara, Yasuaki
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Biologic and prognostic significance of HER2-low and ER-low expressions in de novo metastatic breast cancer
    Ren, Chongxi
    Sun, Jianna
    Kong, Lingjun
    Yang, Yunmei
    Liu, Jiabin
    Zhou, Tong
    Yin, Ruisheng
    Li, Fengying
    Wang, Xin
    Wang, Hongqiao
    Gu, Xiaoying
    Li, Sheng
    Ren, Haixia
    Yu, Hongjun
    Di, Shuping
    Zhao, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes
    Nishimura, Reiki
    Fujiki, Yoshitaka
    Taira, Tetsuhiko
    Miyaki, Toshiko
    Kanemitsu, Shuichi
    Yotsumoto, Daisuke
    Teraoka, Megumi
    Kawano, Junko
    Gondo, Naomi
    Mitsueda, Reiko
    Baba, Shinichi
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yoshiaki
    Sagara, Yasuaki
    CLINICAL BREAST CANCER, 2024, 24 (05) : 431 - 438
  • [28] Inter-Metastasis Heterogeneity of HER2-Low in Metastatic Breast Cancer
    Jaffer, Shabnam
    Bhardwaj, Swati
    LABORATORY INVESTIGATION, 2024, 104 (03) : S179 - S180
  • [29] Clinical and Epidemiologic Significance of HER2-Low Expression in Breast Cancer in the Pathways Study
    Khoury, Thaer
    Ondracek, Rochelle Payne
    Yao, Song
    Mendocino, Lucas
    Davis, Warren
    Omilian, Angela
    Kwan, Marilyn
    Roh, Janise
    D'Addario, Lia
    Valice, Emily
    Fernandez, Daniel
    Ergas, Isaac
    Ambrosone, Christine
    Kushi, Lawrence
    CANCER RESEARCH, 2024, 84 (09)
  • [30] A New Scoring Algorithm to Assess the Prognosis of Primary and Metastatic Breast Cancer with HER2-low Expression
    Miao, Jiaxian
    Shang, Jiuyan
    Liu, Yueping
    LABORATORY INVESTIGATION, 2024, 104 (03) : S222 - S224
12345